Image

Global Sirolimus Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Sirolimus Market, By Strength (0.5mg, 1mg, 2mg, 1mg/mL), Application (Organ Transplant Rejection, Sirolimus Catheter Device, Sirolimus Coated Balloons, Others), Drug Class (MTOR Inhibitors, Selective Immunosuppressants), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Sirolimus Market

Market Analysis and Size

In recent years, the sirolimus market is anticipated to grow rapidly during the forecast period. As per the World Health Organization (WHO), around 100,800 solid organ transplants are conducted worldwide each year, with 69,400 kidney transplants, 20,200 liver transplants, 5,400 heart transplants, 3,400 lung transplants, and 2,400 pancreas transplants being the most common. The increasing transplantation rate and the emergence of lifestyle-related diseases are the major factors leading to the high demand of sirolimus in the market.

Data Bridge Market Research analyses that the sirolimus market was valued at USD 221.0 million in 2021 and is expected to reach USD 316.70 million by 2029, registering a CAGR of 4.60% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Sirolimus, commonly known as rapamycin, is a macrolide molecule that is a strong immunosuppressant with antifungal and anticancer activities. It works by suppressing your immune system and assisting your body in accepting the new organ, so reducing organ rejection following transplant. Sirolimus is also used to coat coronary stents, as well as to treat lymphangioleiomyomatosis (lung disease) and to prevent organ transplant rejection in patients having renal transplants.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Strength (0.5mg, 1mg, 2mg, 1mg/mL), Application (Organ Transplant Rejection, Sirolimus Catheter Device, Sirolimus Coated Balloons, Others), Drug Class (MTOR Inhibitors, Selective Immunosuppressants), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Accord Healthcare (US), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Pfizer Inc. (US), Zydus Cadila (India), Dr. Reddy's Laboratories Ltd. (India), Torrent Pharmaceuticals Ltd. (India), Biocon (India), Concept Medical (US), Intas Pharmaceuticals Ltd (India), Concord Biotech (India), Livzon (China), Actiza Pharmaceutical Private Limited (India), Tiefenbacher API + Ingredients GmbH & Co. KG (Germany), Delphis Pharmaceutical (India)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Sirolimus Market Dynamics

Drivers

  • Increasing instances of organ transplant

The rising transplantation rate is anticipated to influence the market's growth during the forecast period. Furthermore, rising rates of interstitial nephritis, Alagille syndrome, nephrotic syndrome, thrombotic thrombocytopenic purpura (TTP), cystinosis, glomerulonephritis, hemolytic uremic syndrome (HUS), and other nephrotic syndromes are projected to increase need for kidney transplants.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of sirolimus market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the sirolimus market. Additionally, high disposable income and surging prevalence of lifestyle-related disease will result in the expansion of sirolimus market. Along with this, rising geriatric population and technological advancement in organ transplantation will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the sirolimus market growth. Along with this, rising approvals and launches of new sirolimus drugs will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the sirolimus market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with drug distribution and development will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the sirolimus market. Additionally, a decline in clinical visits due to COVID-19 outbreak and side effects of sirolimus such as malignancy, angioedema, increased susceptibility to infection, hypercholesterolemia, hypertriglyceridemia, and proteinuria will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This sirolimus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sirolimus market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Sirolimus market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Sirolimus Market

Over the projected period, the antiplatelet drugs market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the sirolimus market.

Recent Development

  • In November 2021, for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors, the Food and Drug Administration licensed sirolimus protein-bound particles for injectable suspension (albumin-bound). Efficacy was assessed in 31 patients with locally advanced unresectable or metastatic malignant PEComa in the AMPECT (NCT02494570) multicenter, single-arm clinical study. Until disease progression or unacceptable toxicity, patients received 100 mg/m2 sirolimus protein-bound particles on days 1 and 8 of each 21-day cycle.

Global Sirolimus Market Scope

The sirolimus market is segmented on the basis of strength, application, dosage, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Strength

  • 0.5mg
  • 1mg
  • 2mg
  • 1mg/mL

Application

  • Organ Transplant Rejection
  • Sirolimus Catheter Device
  • Sirolimus Coated Balloons
  • Others

Drug Class

  • MTOR Inhibitors
  • Selective Immunosuppressants

Dosage

  • Injection
  • Tablet
  • Others

Route of Administration

  • Oral
  • Intravenous
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Sirolimus Market Regional Analysis/Insights

The sirolimus market is analysed and market size insights and trends are provided by country, strength, application, dosage, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the sirolimus market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the sirolimus market because of the growing number of research and development activities and presence of advanced technology in this region. Additionally, presence of major key players is projected to propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to the increasing presence of generic manufacturers and rising incidences of organ replacement in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Sirolimus Market Share Analysis

The sirolimus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sirolimus market.

Some of the major players operating in the sirolimus market are:

  • Accord Healthcare (US)
  • Apotex Inc. (Canada)
  • Amneal Pharmaceuticals LLC. (US)
  • Pfizer Inc. (US)
  • Zydus Cadila (India)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Torrent Pharmaceuticals Ltd. (India)
  • Biocon (India)
  • Concept Medical (US)
  • Intas Pharmaceuticals Ltd (India)
  • Concord Biotech (India)
  • Livzon (China)
  • Actiza Pharmaceutical Private Limited (India)
  • Tiefenbacher API + Ingredients GmbH & Co. KG (Germany)
  • Delphis Pharmaceutical (India)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for Sirolimus Market is expected USD 316.70 million by 2029.
The Sirolimus Market is to grow at a CAGR of 4.60% during the forecast period of 2022 to 2029
The expansion of the global sirolimus market will be fueled by the emergence of lifestyle-related diseases and rising instances of organ transplant. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global sirolimus market.
The major players operating in the Sirolimus Market are Accord Healthcare (US), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (US), Pfizer Inc. (US), Zydus Cadila (India), Dr. Reddy's Laboratories Ltd. (India), Torrent Pharmaceuticals Ltd. (India), Biocon (India), Concept Medical (US), Intas Pharmaceuticals Ltd (India), Concord Biotech (India), Livzon (China), Actiza Pharmaceutical Private Limited (India), Tiefenbacher API + Ingredients GmbH & Co. KG (Germany), Delphis Pharmaceutical (India).